Olaparib and Radiotherapy in Inoperable Breast Cancer
Status:
Completed
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
The majority of breast cancer patients receive radiotherapy as part of their treatment.
Radiotherapy improves both locoregional control and overall survival. In most patients with
breast cancer the locoregional recurrence rate (LRR) is low, however still high LRRs are
found in certain patient groups, especially in locally advanced, inflammatory and triple
negative breast cancer. Olaparib is a potent PARP inhibitor developed as an anti-cancer drug
for homologous recombination (HR) defected tumors and as a dose intensifier for chemo- and
radiotherapy. The combination of olaparib and radiotherapy is expected to improve
locoregional control and thereby overall survival in both breast cancer patients with a high
probability of locoregional recurrence and patients with HR deficient tumors. However, this
combination treatment has never been tested in humans before. The purpose of this study is to
determine the safety and tolerability of radiotherapy to the breast and regional lymph nodes
with concurrent olaparib.